Fig. 4.
3F6-hIgG1HEK employs both complement and FcγRs to promote opsonophagocytic killing in human blood. (A) S. aureus MW2 survival in human blood (n = 4) without or with cytochalasin D (−/+ CD). (B) S. aureus MW2 survival in human blood (n = 5) in absence or presence of complement inhibitor (−/+ C1 Inh). (C) Opsonophagocytic killing activities of antibody variants compared to hIgG1 and 3F6-hIgG1HEK toward S. aureus MW2 in human blood (n = 10). Data were plotted as the average ± SEM of CFUs after 60 min incubation in blood compared to CFUs of inoculum (set as 100%). Significant differences were identified with the two-tailed Student’s t test (*P < 0.05; **P < 0.01).